Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
Insulet (NASDAQ: PODD) reported solid third-quarter 2017 financial results after the market closed on Thursday.
The drug delivery company, which is a leader in tubeless insulin pump technology with its Omnipod Insulin Management System, delivered revenue growth of 28% -- which exceeded its guidance -- while its loss per share narrowed. The company also raised its revenue guidance for 2017, as it did in both the first and second quarters.
Shares of Insulet have gained 54.2% in 2017 through Thursday, far outpacing the S&P 500's total return of 17.3%.
Source: Fool.com
Insulet Corp. Stock
€178.05
-1.390%
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Insulet Corp..
As a result the target price of 216 € shows a positive potential of 21.31% compared to the current price of 178.05 € for Insulet Corp..
